Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Baricitinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Baricitinib. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2020-001367-88 Sponsor Protocol Number: 25032020 Start Date*: 2020-04-14
    Sponsor Name:Department of Infectious diseases
    Full Title: Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial ...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001354-22 Sponsor Protocol Number: TACTIC-R Start Date*: 2020-05-06
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)
    Medical condition: COVID-19-related complications
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001854-23 Sponsor Protocol Number: AMMURAVID Start Date*: 2020-04-27
    Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI
    Full Title: Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003868-42 Sponsor Protocol Number: R123899 Start Date*: 2020-05-19
    Sponsor Name:University of Manchester
    Full Title: A randomised, phase IIa treatment delayed-start trial of the oral JAK 1/2 inhibitor, baricitinib, in the treatment of adult idiopathic inflammatory myopathy
    Medical condition: Idiopathic Inflammatory Myopathy (IIM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028653 Myositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001321-31 Sponsor Protocol Number: 24032020 Start Date*: 2020-04-11
    Sponsor Name:Hospital Universitario de Fuenlabrada
    Full Title: Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients wit...
    Medical condition: Pneumonia due to SARS Cov2 (COVID-19)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001357-52 Sponsor Protocol Number: EnCovid-hidroxiCLOROQUINA Start Date*: 2020-05-13
    Sponsor Name:IDIVAL
    Full Title: Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in...
    Medical condition: Quimioprophylaxis of SARS-CoV-2 infection with hydroxyloquine (HCQ) in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or J...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021982 Inflammatory disorders following infection HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001246-18 Sponsor Protocol Number: APHP200375 Start Date*: 2020-03-25
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005919-51 Sponsor Protocol Number: REP0220 Start Date*: 2021-01-19
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia.
    Medical condition: COVID-19 Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001052-18 Sponsor Protocol Number: 010 Start Date*: 2020-03-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U...
    Medical condition: Influenza COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) DE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001977-18 Sponsor Protocol Number: 201501252 Start Date*: 2017-09-26
    Sponsor Name:University Medical Center Groningen
    Full Title: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
    Medical condition: Type 2 diabetes and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002793-39 Sponsor Protocol Number: 0451 Start Date*: 2018-03-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003877-91 Sponsor Protocol Number: TOLERA Start Date*: 2019-06-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in...
    Medical condition: Active rheumatoid arthritis with ACPA antibodies failing methotrexate
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001661-21 Sponsor Protocol Number: WP3.protocol.v7 Start Date*: 2022-02-08
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005771-39 Sponsor Protocol Number: RVLO221-02 Start Date*: 2023-03-16
    Sponsor Name:Revolo Biotherapeutics Ltd
    Full Title: A Phase 2, randomised, double-blind, placebo-controlled, dose escalation study to investigate the effects of IRL201805 in participants with moderately to severely active rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005691-26 Sponsor Protocol Number: 201501252 Start Date*: 2016-07-14
    Sponsor Name:University Medical Center Groningen
    Full Title: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation
    Medical condition: Type 1 diabetes with albuminuria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005303-39 Sponsor Protocol Number: M20-466 Start Date*: 2021-08-31
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to ...
    Medical condition: Moderate to Severe Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) SK (Completed) NL (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002340-14 Sponsor Protocol Number: REMAP-CAP Start Date*: 2015-09-16
    Sponsor Name:University Medical Center Utrecht
    Full Title: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)
    Medical condition: Severe Community Acquired Pneumonia COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Completed) BE (Trial now transitioned) DE (Ongoing) HR (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned) FI (Ongoing) IT (Trial now transitioned) CZ (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:48:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA